Drug Trial Radar · NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Screening
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Conditions
- Obesity
- Overweight
- Type 2 Diabetes
Interventions
OrforglipronDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Allocated to Each StudyTime frame: Baseline to Week 4
Locations
80 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona
Norcal Endocrinology & Internal Medicine
San Ramon, California
Southern California Clinical Research
Santa Ana, California
Care Access - Thousand Oaks
Thousand Oaks, California
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida
Innovation Medical Research Center - Fort Lauderdale
Fort Lauderdale, Florida
Indago Research & Health Center, Inc
Hialeah, Florida
Encore Medical Research
Hollywood, Florida
West Orange Endocrinology P.A.
Ocoee, Florida
Care Access - Tampa
Tampa, Florida
Conquest Research
Winter Park, Florida
Accel Research Sites - NeuroStudies Clinical Research Unit
Decatur, Georgia
Care Access - Decatur
Decatur, Georgia
Javara - Privia Medical Group Georgia - Savannah
Savannah, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Solaris Clinical Research
Meridian, Idaho
Care Access - New Iberia
New Iberia, Louisiana
Endocrine and Metabolic Consultants
Rockville, Maryland
Javara - Privia Medical Group - Silver Spring
Silver Spring, Maryland
Great Lakes Research Group, Inc.
Bay City, Michigan
Boeson Research MSO
Missoula, Montana
Javara - Nevada Health Centers - Carson City
Carson City, Nevada
The Machuca Foundation
Las Vegas, Nevada
University of North Carolina Medical Center
Chapel Hill, North Carolina
Javara - Tryon Medical Partners
Charlotte, North Carolina
Care Access - Fayetteville
Fayetteville, North Carolina
The Corvallis Clinic, P.C.
Corvallis, Oregon
Clinical Research of Philadelphia
Philadelphia, Pennsylvania
Frontier Clinical Research, LLC
Smithfield, Pennsylvania
Velocity Clinical Research, Dallas
Dallas, Texas
Biopharma Informatic, LLC
Houston, Texas
Activian Clinical Research
Kingwood, Texas
Texas Valley Clinical Research (TVCR) - Mission
Mission, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
CARE - Centro de Alergia y Enfermedades Respiratorias
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Centro Médico Viamonte
Buenos Aires, Argentina
Instituto Centenario
CABA, Argentina
Instituto Médico Catamarca IMEC
Rosario, Argentina
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.